Name | Nezulcitinib |
---|
Description | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2]. |
---|---|
Related Catalog | |
Target |
JAK |
In Vitro | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor[1][2]. |
References |
[1]. Theravance's nezulcitinib fails to meet Phase II goals in Covid-19 |
Molecular Formula | C30H37N7O2 |
---|---|
Molecular Weight | 527.66 |